by Maria Zannes | Oct 15, 2025 | Press Releases
SAN ANTONIO, TX — October 15, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced...
by Maria Zannes | Oct 9, 2025 | Press Releases
SAN ANTONIO, Texas (October 9, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the previously announced definitive...
by Maria Zannes | Oct 8, 2025 | Press Releases
SAN ANTONIO, Texas (October 8, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into definitive agreements for...
by Maria Zannes | Oct 7, 2025 | Press Releases
SAN ANTONIO, TX – October 7, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath® Lung diagnostic test for lung cancer...
by Maria Zannes | Sep 29, 2025 | Press Releases
SAN ANTONIO, TX – September 29, 2025 – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a public offering of securities as...
by Maria Zannes | Sep 26, 2025 | Press Releases
Noninvasive diagnostic test again leads to detecting Stage 1A lung cancer SAN ANTONIO, TX – September 26, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases,...
